Asset Details
Do you wish to reserve the book?
The efficacy and safety of intralesional Candida vaccine versus topical diphencyproprobenone in immunotherapy of verruca vulgaris: A randomized comparative study
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The efficacy and safety of intralesional Candida vaccine versus topical diphencyproprobenone in immunotherapy of verruca vulgaris: A randomized comparative study
Do you wish to request the book?
The efficacy and safety of intralesional Candida vaccine versus topical diphencyproprobenone in immunotherapy of verruca vulgaris: A randomized comparative study
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The efficacy and safety of intralesional Candida vaccine versus topical diphencyproprobenone in immunotherapy of verruca vulgaris: A randomized comparative study
2023
Overview
Various therapeutic options are available for verruca. While physical destruction may be associated with scarring, immunotherapy may be effective in treating warts through stimulating body immune response. The objective of the study was to compare the efficacy, safety, and outcome of
Candida
antigen vs diphencyprone (DPCP) in the treatment of warts. Fifty patients were randomly assigned to receive either intralesional
Candida
antigen every 3 weeks or weekly DPCP application. Both treatments were applied only to the mother wart. Lesions’ clearance and associated side effects were observed up to 4 weeks after treatment. Two blinded physicians evaluated photos of warts before and 4 weeks after the end of treatment. Both modalities granted wart clearance and/or improvement with no statistically significant difference; however,
Candida
antigen was significantly better in clearing adjacent untreated warts (
p
= 0.046). Fewer side effects were observed among the
Candida
antigen group. The response was duration associated in the
Candida
groups only. Intralesional
Candida
antigen injection and DPCP treatments for warts yielded improvement with superiority of
Candida
injection in eradicating distant lesions and fewer side effects. A shorter wart duration may be associated with a better therapeutic response with
Candida
antigen.
Publisher
Springer Berlin Heidelberg,Springer Nature B.V
Subject
/ Antigens, Fungal - administration & dosage
/ Antigens, Fungal - adverse effects
/ Candida
/ Cyclopropanes - administration & dosage
/ Cyclopropanes - adverse effects
/ Drug-Related Side Effects and Adverse Reactions
/ Humans
/ Immunotherapy - adverse effects
/ Medicine
/ Patients
/ Vaccines
/ Vaccines - administration & dosage
/ Warts
